Meg Jardine's Publications

About Meg Jardine's Publications

Honorary Professorial Fellow, The George Institute for Global Health
  • Associate Professor, Faculty of Medicine, UNSW Sydney

  • Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet Date published:

  • Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR

    Clinical Journal of the American Society of Nephrology Date published:

  • WCN23-1085 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATY- THE ALIGN STUDY

    Kidney International Reports Date published:

  • Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD

    Clinical Journal of the American Society of Nephrology Date published:

  • Hara D; Campain A; Hockham C; Kang A; Young T; Jun M; Rogers K; Cass A; Pollock C; Zoungas S; Foote C; Peiris D; Jardine M, 2023, 'ADHERENCE AND LONG-TERM TRENDS IN UPTAKE OF CARDIOPROTECTIVE MEDICATION FOLLOWING AN ACUTE MYOCARDIAL INFARCTION AMONG PEOPLE WITH DIABETES AND CKD - A PROSPECTIVE POPULATION-BASED STUDY

    Date published:

  • Prognostic Significance of Baseline Blood Glucose Levels and Glucose Variability in Severe Acute Kidney Injury: A Secondary Analysis from the RENAL Study

    Journal of Clinical Medicine Date published:

  • Study protocol for Vascular Access outcome measure for function: a vaLidation study In hemoDialysis (VALID)

    BMC Nephrology Date published:

  • Dialysis Dose and Adequacy for Hemodialysis

    Evidence‐Based Nephrology Date published:

  • Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial

    BMJ Date published:

  • Comparing survival in patients with chronic kidney disease across three countries - Results from the study of heart and renal protection-extended review

    Nephrology Date published:

  • Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

    The Lancet Date published:

  • Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria

    Journal of the American College of Cardiology Date published:

  • Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study

    European Heart Journal - Quality of Care and Clinical Outcomes Date published:

  • Digital health technologies to support medication adherence in chronic kidney disease

    Nephrology Date published:

  • Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

    Diabetes, Obesity and Metabolism Date published: